Chi H, et al. – Researchers here aimed to focus on the durability of response after hepatitis B surface antigen seroclearance during nucleos(t)ide analogue treatment in a multiethnic cohort of chronic hepatitis B patients. In 70 chronic hepatitis B patients with hepatitis B surface antigen seroclearance during nucleos(t)ide analogue therapy, findings revealed sustained response in all 54 patients who discontinued treatment. Clinically they identified no significant relapses as indicated by high hepatitis B virus DNA and ALT levels. Thereby suggesting that anti–HBs positivity would not be required to ensure sustained off–treatment response.